drugset / Trial / NCT00837031
Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the Pancreas
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the 6-month overall survival, safety, and tolerability of lenalidomide in combination with standard gemcitabine as first-line treatment for patients with metastatic pancreatic cancer.
Timeline
- Start
- 2009-02
- Primary completion
- 2010-04
- Completion
- 2012-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | Lenalidomide | Other / unclassified | 20 mg | Oral |
| Subject | Lenalidomide | Other / unclassified | 25 mg | Oral |